United Capital Financial Advisers, LLC Arcturus Therapeutics Holdings Inc. Transaction History

United Capital Financial Advisers, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$13.05 - $22.13 $143 - $243	11 Added 0.04%	24,948 $370,000
Q2 2022 Aug 11, 2022	BUY	$12.26 - $31.17 $12 - $31	1 Added 0.0%	24,937 $393,000
Q1 2022 May 16, 2022	BUY	$17.64 - $39.57 $194 - $435	11 Added 0.04%	24,936 $672,000
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $171 - $237	5 Added 0.02%	24,925 $922,000
Q2 2021 Aug 13, 2021	SELL	$25.79 - $42.11 $128 - $210	-5 Reduced 0.02%	24,920 $843,000
Q1 2021 May 14, 2021	SELL	$38.75 - $86.92 $51,963 - $116,559	-1,341 Reduced 5.11%	24,925 $1.03 Million
Q4 2020 Feb 17, 2021	SELL	$34.61 - $123.66 $73,719 - $263,395	-2,130 Reduced 7.5%	26,266 $1.14 Million
Q3 2020 Nov 13, 2020	SELL	$37.49 - $63.19 $45,137 - $76,080	-1,204 Reduced 4.07%	28,396 $1.22 Million
Q3 2019 Nov 14, 2019	BUY	$8.8 - $14.5 $20,240 - $33,350	2,300 Added 8.42%	29,600 $304,000
Q2 2019 Aug 13, 2019	BUY	$5.78 - $9.79 $157,794 - $267,267	27,300 New	27,300 $258,000

179

25.6M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $411M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.